These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 6417130

  • 1. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
    Monks A, Anderson LW, Strong J, Cysyk RL.
    J Biol Chem; 1983 Nov 25; 258(22):13564-9. PubMed ID: 6417130
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
    Johnson RK, Inouye T, Goldin A, Stark GR.
    Cancer Res; 1976 Aug 25; 36(8):2720-5. PubMed ID: 1064466
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
    Jayaram HN, Cooney DA, Vistica DT, Kariya S, Johnson RK.
    Cancer Treat Rep; 1979 Aug 25; 63(8):1291-302. PubMed ID: 476706
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells.
    Moyer JD, Smith PA, Levy EJ, Handschumacher RE.
    Cancer Res; 1982 Nov 25; 42(11):4525-31. PubMed ID: 7127293
    [Abstract] [Full Text] [Related]

  • 9. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
    Moore EC.
    Biochem Pharmacol; 1982 Oct 15; 31(20):3313-6. PubMed ID: 7150357
    [Abstract] [Full Text] [Related]

  • 10. Effect of high-protein diet on pyrimidine synthesis and response to PALA in mouse tissues.
    Zaharevitz DW, Grubb MF, Hyman R, Chisena C, Cysyk RL.
    J Natl Cancer Inst; 1993 Apr 21; 85(8):662-6. PubMed ID: 8468725
    [Abstract] [Full Text] [Related]

  • 11. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
    Moore EC, Friedman J, Valdivieso M, Plunkett W, Marti JR, Russ J, Loo TL.
    Biochem Pharmacol; 1982 Oct 15; 31(20):3317-21. PubMed ID: 7150358
    [Abstract] [Full Text] [Related]

  • 12. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Ardalan B, Jayaram HN, Johnson RK.
    Cancer Res; 1983 Apr 15; 43(4):1598-601. PubMed ID: 6831405
    [Abstract] [Full Text] [Related]

  • 13. Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells.
    Grant S, Rauscher F, Jakubowski A, Cadman E.
    Cancer Res; 1981 Feb 15; 41(2):410-8. PubMed ID: 6160908
    [Abstract] [Full Text] [Related]

  • 14. Comparative physiological disposition of N-(phosphonacetyl)-L-aspartate in several animal species after intravenous and oral administration.
    Chadwick M, Silveira DM, MacGregor JA, Branfman AR, Liss RH, Yesair DW.
    Cancer Res; 1982 Feb 15; 42(2):627-32. PubMed ID: 7055806
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro.
    Leyva A, Appel H, Smith P, Lankelma J, Pinedo HM.
    Cancer Lett; 1981 Mar 15; 12(1-2):169-73. PubMed ID: 7273001
    [Abstract] [Full Text] [Related]

  • 16. Overproduction of the first three enzymes of pyrimidine nucleotide biosynthesis in Drosophila cells resistant to N-phosphonacetyl-L-aspartate.
    Laval M, Azou Y, Giorgi D, Rosset R.
    Exp Cell Res; 1986 Apr 15; 163(2):381-95. PubMed ID: 2869965
    [Abstract] [Full Text] [Related]

  • 17. Effect of plasma concentrations of uridine on pyrimidine biosynthesis in cultured L1210 cells.
    Karle JM, Anderson LW, Cysyk RL.
    J Biol Chem; 1984 Jan 10; 259(1):67-72. PubMed ID: 6323418
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.
    Miller AA, Moore EC, Hurlbert RB, Benvenuto JA, Loo TL.
    Cancer Res; 1983 Jun 10; 43(6):2565-70. PubMed ID: 6189583
    [Abstract] [Full Text] [Related]

  • 19. Kinetic parameters of aspartate transcarbamylase in human normal and tumoral cell lines.
    Baillon J, Guichard M, Malaise EP, Hervé G.
    Cancer Res; 1983 May 10; 43(5):2277-82. PubMed ID: 6831451
    [Abstract] [Full Text] [Related]

  • 20. PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
    Yang JL, Fernandes DJ, Wheeler KT, Capizzi RL.
    Int J Radiat Oncol Biol Phys; 1996 Mar 15; 34(5):1073-9. PubMed ID: 8600090
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.